Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2007 2
2008 2
2009 2
2010 2
2011 3
2012 4
2013 9
2014 7
2015 8
2016 10
2017 10
2018 10
2019 9
2020 12
2021 10
2022 29
2023 24
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, Bennouna J, Kato K, Shen L, Enzinger P, Qin SK, Ferreira P, Chen J, Girotto G, de la Fouchardiere C, Senellart H, Al-Rajabi R, Lordick F, Wang R, Suryawanshi S, Bhagia P, Kang SP, Metges JP; KEYNOTE-181 Investigators. Kojima T, et al. J Clin Oncol. 2020 Dec 10;38(35):4138-4148. doi: 10.1200/JCO.20.01888. Epub 2020 Oct 7. J Clin Oncol. 2020. PMID: 33026938 Clinical Trial.
The prevalence of electronic cigarettes vaping globally: a systematic review and meta-analysis.
Tehrani H, Rajabi A, Ghelichi-Ghojogh M, Nejatian M, Jafari A. Tehrani H, et al. Arch Public Health. 2022 Nov 21;80(1):240. doi: 10.1186/s13690-022-00998-w. Arch Public Health. 2022. PMID: 36415010 Free PMC article.
RESULTS: In this study, the lifetime and current prevalence of e-cigarettes vaping globally were 23% and 11%, respectively. Lifetime and current prevalence of e-cigarettes vaping in women were 16% and 8%, respectively. ...CONCLUSIONS: Based on the results of this st …
RESULTS: In this study, the lifetime and current prevalence of e-cigarettes vaping globally were 23% and 11%, respectively. Lifetime …
Global prevalence of nosocomial infection: A systematic review and meta-analysis.
Raoofi S, Pashazadeh Kan F, Rafiei S, Hosseinipalangi Z, Noorani Mejareh Z, Khani S, Abdollahi B, Seyghalani Talab F, Sanaei M, Zarabi F, Dolati Y, Ahmadi N, Raoofi N, Sarhadi Y, Masoumi M, Sadat Hosseini B, Vali N, Gholamali N, Asadi S, Ahmadi S, Ahmadi B, Beiramy Chomalu Z, Asadollahi E, Rajabi M, Gharagozloo D, Nejatifar Z, Soheylirad R, Jalali S, Aghajani F, Navidriahy M, Deylami S, Nasiri M, Zareei M, Golmohammadi Z, Shabani H, Torabi F, Shabaninejad H, Nemati A, Amerzadeh M, Aryankhesal A, Ghashghaee A. Raoofi S, et al. PLoS One. 2023 Jan 27;18(1):e0274248. doi: 10.1371/journal.pone.0274248. eCollection 2023. PLoS One. 2023. PMID: 36706112 Free PMC article.
Besides, AFR prevalence in central Africa is higher than in other parts of the world by 0.27 (95% CI, 0.22-0.34). Besides, E. coli infected patients more than other micro-organisms such as Coagulase-negative staphylococci, Staphylococcus spp. and Pseudomonas aeruginosa. .. …
Besides, AFR prevalence in central Africa is higher than in other parts of the world by 0.27 (95% CI, 0.22-0.34). Besides, E. coli in …
Carbon-chalcogen bond formation initiated by [Al(NON(Dipp))(E)](-) anions containing Al-E{16} (E{16} = S, Se) multiple bonds.
Evans MJ, Anker MD, McMullin CL, Neale SE, Rajabi NA, Coles MP. Evans MJ, et al. Chem Sci. 2022 Mar 31;13(16):4635-4646. doi: 10.1039/d2sc01064j. eCollection 2022 Apr 20. Chem Sci. 2022. PMID: 35656129 Free PMC article.
The reaction of the sulfido and selenido anions K[Al(NON(Dipp))(E)] (E = S, Se) with CO(2) afforded K[Al(NON(Dipp))(kappa(2) E,O-EC{O}O)] containing the thio- and seleno-carbonate groups respectively, consistent with a [2 + 2]-cycloaddition reaction and C- …
The reaction of the sulfido and selenido anions K[Al(NON(Dipp))(E)] (E = S, Se) with CO(2) afforded K[Al(NON(Dipp))(kappa(2) …
Targeting Sirtuins: Substrate Specificity and Inhibitor Design.
Rajabi N, Galleano I, Madsen AS, Olsen CA. Rajabi N, et al. Prog Mol Biol Transl Sci. 2018;154:25-69. doi: 10.1016/bs.pmbts.2017.11.003. Prog Mol Biol Transl Sci. 2018. PMID: 29413177 Review.
Lysine residues across the proteome are modified by posttranslational modifications (PTMs) that significantly enhance the structural and functional diversity of proteins. For lysine, the most abundant PTM is e-N-acetyllysine (Kac), which plays numerous roles in regulation …
Lysine residues across the proteome are modified by posttranslational modifications (PTMs) that significantly enhance the structural and fun …
Mif-deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis.
Schmitz C, Noels H, El Bounkari O, Straussfeld E, Megens RTA, Sternkopf M, Alampour-Rajabi S, Krammer C, Tilstam PV, Gerdes N, Bürger C, Kapurniotu A, Bucala R, Jankowski J, Weber C, Bernhagen J. Schmitz C, et al. FASEB J. 2018 Aug;32(8):4428-4443. doi: 10.1096/fj.201800058R. Epub 2018 Mar 15. FASEB J. 2018. PMID: 29543531 Free PMC article.
Targeting MIF may induce protective B-cell responses in atherosclerosis.-Schmitz, C., Noels, H., El Bounkari, O., Straussfeld, E., Megens, R. T. A., Sternkopf, M., Alampour-Rajabi, S., Krammer, C., Tilstam, P. ...
Targeting MIF may induce protective B-cell responses in atherosclerosis.-Schmitz, C., Noels, H., El Bounkari, O., Straussfeld, E., Me …
Brazilian XP-E siblings carrying a novel DDB2 variant developed early-onset melanoma: a case report.
de Souza Timoteo AR, Pinheiro de Almeida IC, Yurchenko AA, de Miranda Henriques SR, de Souza Segundo P, Rajabi F, Nikolaev S, Petta TB. de Souza Timoteo AR, et al. BMC Med Genomics. 2023 Aug 12;16(1):186. doi: 10.1186/s12920-023-01622-8. BMC Med Genomics. 2023. PMID: 37573316 Free PMC article.
BACKGROUND: Xeroderma pigmentosum group E (XP-E) is one of the least common forms of XP, a rare syndrome where patients are prone to develop skin cancer in exposed sunlight areas. XP-E patients are generally not diagnosed until they are adults due to the mild …
BACKGROUND: Xeroderma pigmentosum group E (XP-E) is one of the least common forms of XP, a rare syndrome where patients are pr …
Rare pathogenic variants in WNK3 cause X-linked intellectual disability.
Küry S, Zhang J, Besnard T, Caro-Llopis A, Zeng X, Robert SM, Josiah SS, Kiziltug E, Denommé-Pichon AS, Cogné B, Kundishora AJ, Hao LT, Li H, Stevenson RE, Louie RJ, Deb W, Torti E, Vignard V, McWalter K, Raymond FL, Rajabi F, Ranza E, Grozeva D, Coury SA, Blanc X, Brischoux-Boucher E, Keren B, Õunap K, Reinson K, Ilves P, Wentzensen IM, Barr EE, Guihard SH, Charles P, Seaby EG, Monaghan KG, Rio M, van Bever Y, van Slegtenhorst M, Chung WK, Wilson A, Quinquis D, Bréhéret F, Retterer K, Lindenbaum P, Scalais E, Rhodes L, Stouffs K, Pereira EM, Berger SM, Milla SS, Jaykumar AB, Cobb MH, Panchagnula S, Duy PQ, Vincent M, Mercier S, Gilbert-Dussardier B, Le Guillou X, Audebert-Bellanger S, Odent S, Schmitt S, Boisseau P, Bonneau D, Toutain A, Colin E, Pasquier L, Redon R, Bouman A, Rosenfeld JA, Friez MJ, Pérez-Peña H, Akhtar Rizvi SR, Haider S, Antonarakis SE, Schwartz CE, Martínez F, Bézieau S, Kahle KT, Isidor B. Küry S, et al. Genet Med. 2022 Sep;24(9):1941-1951. doi: 10.1016/j.gim.2022.05.009. Epub 2022 Jun 9. Genet Med. 2022. PMID: 35678782 Free article.
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.
Saeed A, Park R, Dai J, Al-Rajabi R, Kasi A, Baranda J, Williamson S, Saeed A, Ripp J, Collins Z, Mulvaney K, Shugrue M, Firth-Braun J, Godwin AK, Madan R, Phadnis M, Sun W. Saeed A, et al. Cell Rep Med. 2023 Feb 21;4(2):100916. doi: 10.1016/j.xcrm.2023.100916. Epub 2023 Jan 25. Cell Rep Med. 2023. PMID: 36702123 Free PMC article. Clinical Trial.
This is the phase Ib part of the phase I/II CAMILLA trial evaluating cabozantinib plus durvalumab in advanced chemo-refractory proficient mismatch repair or microsatellite stable (pMMR/MSS) gastrointestinal malignancies including gastric/gastroesophageal junction/esophageal (G/GE …
This is the phase Ib part of the phase I/II CAMILLA trial evaluating cabozantinib plus durvalumab in advanced chemo-refractory proficient mi …
142 results